Citations (79)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Abdulmajeed Alshowair, Saleh Altamimi, Faisal Alruhaimi, Ali Tolba, Alhanouf Almeshari, Rehab Almubrick & Amro Abdel-Azeem. (2022) Assessment of Primary Health Care Specialized Reference Clinics in Riyadh First Health Cluster: Outcome, Cost-Effectiveness and Patient Satisfaction. ClinicoEconomics and Outcomes Research 14, pages 371-381.
Read now
Read now
C. Beauchemin, K. Guinan, D. Claveau, S. Frédéric Dufresne & C. Rotstein. (2022) Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada. Expert Review of Pharmacoeconomics & Outcomes Research 22:5, pages 805-814.
Read now
Read now
Fernando Albuquerque De Almeida, Maiwenn Al, Ron Koymans, Kadir Caliskan, Ankie Kerstens & Johan L. Severens. (2018) Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models. Expert Review of Pharmacoeconomics & Outcomes Research 18:2, pages 161-175.
Read now
Read now
Shepherd Shamu, Simbarashe Rusakaniko & Charles Hongoro. (2016) Prioritizing health system and disease burden factors: an evaluation of the net benefit of transferring health technology interventions to different districts in Zimbabwe. ClinicoEconomics and Outcomes Research 8, pages 695-705.
Read now
Read now
Valentina Lorenzoni, Leopoldo Trieste & Giuseppe Turchetti. (2015) The cost–effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet. Expert Review of Pharmacoeconomics & Outcomes Research 15:4, pages 611-624.
Read now
Read now
Rainel Sánchez-de la Rosa, Eliazar Sabater, Miguel Angel Casado & Rafael Arroyo. (2012) Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Journal of Medical Economics 15:3, pages 424-433.
Read now
Read now
Ron Goeree, Jing He, Daria O’Reilly, Jean-Eric Tarride, Feng Xie, Morgan Lim & Natasha Burke. (2011) Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. ClinicoEconomics and Outcomes Research 3, pages 89-104.
Read now
Read now
Keith Freeman. (2011) The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis – an introduction. Current Medical Research and Opinion 27:1, pages 197-203.
Read now
Read now
M. K. Sidhu, A. K. van Engen, J. Kleintjens, O. Schoeman & M. Palazzo. (2009) Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Current Medical Research and Opinion 25:8, pages 2049-2059.
Read now
Read now
O. A. Cornely, M. Sidhu, I. Odeyemi, A. K. van Engen, J. M. van der Waal & O. Schoeman. (2008) Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Current Medical Research and Opinion 24:6, pages 1743-1753.
Read now
Read now
Lotte Steuten, Laura Vallejo-Torres, Terry Young & Martin Buxton. (2008) Transferability of economic evaluations of medical technologies: a new technology for orthopedic surgery. Expert Review of Medical Devices 5:3, pages 329-336.
Read now
Read now
Lea M Dijksman, Rudolf W Poolman, Mohit Bhandari, Ron Goeree, Jean-Eric Tarride & on behalf of the International Evidence–Based Orthopaedic Surgery Working Group. (2008) Money matters: what to look for in an economic analysis. Acta Orthopaedica 79:1, pages 1-11.
Read now
Read now
Articles from other publishers (67)
David A. Ganz, Thomas M. Gill, David B. Reuben, Shalender Bhasin, Nancy K. Latham, Peter Peduzzi & Erich J. Greene. (2023) Costs of fall injuries in the STRIDE study: an economic evaluation of healthcare system heterogeneity and heterogeneity of treatment effect. Cost Effectiveness and Resource Allocation 21:1.
Crossref
Crossref
Rachael Taylor, Deborah Sullivan, Penny Reeves, Nicola Kerr, Amy Sawyer, Emma Schwartzkoff, Andrew Bailey, Christopher Williams & Alexis Hure. (2023) A Scoping Review of Economic Evaluations to Inform the Reorientation of Preventive Health Services in Australia. International Journal of Environmental Research and Public Health 20:12, pages 6139.
Crossref
Crossref
Nicolás Armijo, Manuel Espinoza, Paula Zamorano, Daniela Lahoz, Tamara Yañez & Carlos Balmaceda. (2022) Analisis del proceso de Evaluación de Tecnologías Sanitarias del Sistema de Protección Financiera Para Diagnósticos y Tratamientos de Alto Costo en Chile (Ley Ricarte Soto). Value in Health Regional Issues 32, pages 95-101.
Crossref
Crossref
John J. Riva, Meha Bhatt, Carolina C. Martins, David J. Brunarski, Jason W. Busse, Feng Xie, Holger J. Schünemann & Jan L. Brozek. (2022) Indirectness (transferability) is critical when considering existing economic evaluations for GRADE clinical practice guidelines: a systematic review. Journal of Clinical Epidemiology 148, pages 81-92.
Crossref
Crossref
Angelique de Rijk, Karina Carrasco-Negüe & Inge Houkes. (2022) The Cross-Country Comparison Model for Labor Participation (CCC Model for LP) of Persons with Chronic Diseases. Journal of Occupational Rehabilitation 32:2, pages 225-240.
Crossref
Crossref
Yi Hsuan Chen, Dominique Molenaar, Carin A. Uyl-de Groot, Marco van Vulpen & Hedwig M. Blommestein. (2022) Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review. Cancers 14:10, pages 2444.
Crossref
Crossref
Sara G McCleskey, Lili Shek, Jonathan Grein, Hiroshi Gotanda, Laura Anderson, Paul G Shekelle, Emmett Keeler, Sally Morton & Teryl K Nuckols. (2022) Economic evaluation of quality improvement interventions to prevent catheter-associated urinary tract infections in the hospital setting: a systematic review. BMJ Quality & Safety 31:4, pages 308-321.
Crossref
Crossref
Lieke Fleur Heupink, Elizabeth Fleur Peacocke, Ingvil Sæterdal, Lumbwe Chola & Katrine Frønsdal. (2022) Considerations for transferability of health technology assessments: a scoping review of tools, methods, and practices. International Journal of Technology Assessment in Health Care 38:1.
Crossref
Crossref
Marianela Castillo-Riquelme, Bernardo Martorell & Mauricio Baeza Paredes. 2022. Introduction to Economic Evaluation in Oral Health Care. Introduction to Economic Evaluation in Oral Health Care
183
206
.
Annesha White, Meenakshi Srinivasan, La Marcus Wingate, Samuel Peasah & Marc Fleming. (2021) Development of a pharmacoeconomic registry: an example using hormonal contraceptives. Health Economics Review 11:1.
Crossref
Crossref
Leticia García-Mochón, Joan Rovira Forns & Jaime Espin. (2021) Cost transferability problems in economic evaluation as a framework for an European health care and social costs database. Cost Effectiveness and Resource Allocation 19:1.
Crossref
Crossref
Julia Simões Corrêa Galendi, Carlos Antonio Caramori, Clarissa Lemmen, Dirk Müller & Stephanie Stock. (2021) Expectations for the Development of Health Technology Assessment in Brazil. International Journal of Environmental Research and Public Health 18:22, pages 11912.
Crossref
Crossref
Cassandra Nemzoff, Francis Ruiz, Kalipso Chalkidou, Abha Mehndiratta, Lorna Guinness, Francoise Cluzeau & Hiral Shah. (2021) Adaptive health technology assessment to facilitate priority setting in low- and middle-income countries. BMJ Global Health 6:4, pages e004549.
Crossref
Crossref
Camilla Nystrand, Mihretab Gebreslassie, Richard Ssegonja, Inna Feldman & Filipa Sampaio. (2021) A systematic review of economic evaluations of public health interventions targeting alcohol, tobacco, illicit drug use and problematic gambling: Using a case study to assess transferability. Health Policy 125:1, pages 54-74.
Crossref
Crossref
Bianca Bech, Jette Primdahl, Astrid van Tubergen, Marieke Voshaar, Heidi A Zangi, Lurdes Barbosa, Carina Boström, Boryana Boteva, Francesco Carubbi, Françoise Fayet, Ricardo J O Ferreira, Kirsten Hoeper, Agnes Kocher, Marja Leena Kukkurainen, Vivienne Lion, Patricia Minnock, Antonella Moretti, Mwidimi Ndosi, Milena Pavic Nikolic, Michael Schirmer, Hana Smucrova, Jenny de la Torre-Aboki, Jennifer Waite-Jones & Yvonne van Eijk-Hustings. (2020) 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Annals of the Rheumatic Diseases 79:1, pages 61-68.
Crossref
Crossref
G M W Bjørnelv, S Dueland, P-D Line, P Joranger, Å A Fretland, B Edwin, H Sørbye & E Aas. (2019) Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. British Journal of Surgery 106:1, pages 132-141.
Crossref
Crossref
Puttarin Kulchaitanaroaj, Zoltán Kaló, Robert West, Kei Long Cheung, Silvia Evers, Zoltán Vokó, Mickael Hiligsmann, Hein de Vries, Lesley Owen, Marta Trapero-Bertran, Reiner Leidl & Subhash Pokhrel. (2018) Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study. BMC Health Services Research 18:1.
Crossref
Crossref
Teryl K. Nuckols, Emmett Keeler, Laura J. Anderson, Jonas Green, Sally C. Morton, Brian J. Doyle, Kanaka Shetty, Aziza Arifkhanova, Marika Booth, Roberta Shanman & Paul Shekelle. (2018) Economic Evaluation of Quality Improvement Interventions Designed to Improve Glycemic Control in Diabetes: A Systematic Review and Weighted Regression Analysis. Diabetes Care 41:5, pages 985-993.
Crossref
Crossref
Torbjørn Wisløff, Richard White, Olav Dalgard, Ellen J. Amundsen, Hinta Meijerink, Astrid Louise Løvlie & Hilde Kløvstad. (2018) Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. PharmacoEconomics 36:5, pages 591-601.
Crossref
Crossref
Florien M. Kruse, Niek W. Stadhouders, Eddy M. Adang, Stef Groenewoud & Patrick P.T. Jeurissen. (2018) Do private hospitals outperform public hospitals regarding efficiency, accessibility, and quality of care in the European Union? A literature review. The International Journal of Health Planning and Management 33:2, pages e434-e453.
Crossref
Crossref
Wendy L. St. Peter, Lori D. Wazny, Eric Weinhandl, Katie E. Cardone & Joanna Q. Hudson. (2017) A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?. Drugs 77:11, pages 1155-1186.
Crossref
Crossref
Zoltan Vokó, Kei Long Cheung, Judit Józwiak-Hagymásy, Silke Wolfenstetter, Teresa Jones, Celia Muñoz, Silvia M.A.A. Evers, Mickaël Hiligsmann, Hein de Vries & Subhash Pokhrel. (2016) Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey. Health Research Policy and Systems 14:1.
Crossref
Crossref
Rana Rizk. (2016) Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go. BMC Nephrology 17:1.
Crossref
Crossref
Celia Muñoz, Marta Trapero-Bertran, Kei Long Cheung, Silvia Evers, Mickaël Hiligsmann, Hein de Vries & Ángel López-Nicolás. (2016) Herramienta de retorno de la inversión en control del tabaquismo: ¿qué opinan aquellos que toman decisiones?. Gaceta Sanitaria 30:2, pages 121-125.
Crossref
Crossref
Lan Gao, Hao Hu, Fei-Li Zhao & Shu-Chuen Li. (2016) Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples. PLOS ONE 11:1, pages e0147169.
Crossref
Crossref
Fabien CalcagnoSabrina LenobleZaher LakkisThierry NguyenSamuel LimatChristophe BorgMarine JaryStefano KimVirginie Nerich. (2016) Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice. Clinical Medicine Insights: Oncology 10, pages CMO.S38335.
Crossref
Crossref
Christian E. H. BoehlerJoanne Lord. (2015) Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries. Medical Decision Making 36:1, pages 31-47.
Crossref
Crossref
Oliver Damm, Bernhard Ultsch, Johannes Horn, Rafael T. Mikolajczyk, Wolfgang Greiner & Ole Wichmann. (2015) Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health 15:1.
Crossref
Crossref
Christian EH Boehler, Gimon de Graaf, Lotte Steuten, Yaling Yang & Fabienne Abadie. (2015) Development of a web-based tool for the assessment of health and economic outcomes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). BMC Medical Informatics and Decision Making 15:S3.
Crossref
Crossref
Adrian Gheorghe, Tracy Roberts, Karla Hemming & Melanie Calvert. (2015) Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index. PharmacoEconomics 33:11, pages 1195-1214.
Crossref
Crossref
Ana Lozano-Blázquez, Rumona Dickson, María-Dolores Fraga-Fuentes, Fernando Martínez-Martínez & Miguel-Ángel Calleja-Hernández. (2015) Differences in cancer drug assessment between Spain and the United Kingdom. European Journal of Cancer 51:13, pages 1843-1852.
Crossref
Crossref
Thomas Grochtdreis, Christian Brettschneider, Annemarie Wegener, Birgit Watzke, Steffi Riedel-Heller, Martin Härter & Hans-Helmut König. (2015) Cost-Effectiveness of Collaborative Care for the Treatment of Depressive Disorders in Primary Care: A Systematic Review. PLOS ONE 10:5, pages e0123078.
Crossref
Crossref
Adrian Gheorghe, Tracy Roberts, Thomas D. Pinkney, Dion G. Morton & Melanie Calvert. (2015) Rational Centre Selection for RCTs with a Parallel Economic Evaluation-the Next Step Towards Increased Generalisability?. Health Economics 24:4, pages 498-504.
Crossref
Crossref
Olena Mandrik, Saskia Knies, Zoltan Kalo & Johan L. Severens. (2016) REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. International Journal of Technology Assessment in Health Care 31:6, pages 434-441.
Crossref
Crossref
Michael Drummond, Federico Augustovski, Zoltán Kaló, Bong-Min Yang, Andres Pichon-Riviere, Eun-Young Bae & Sachin Kamal-Bahl. (2016) CHALLENGES FACED IN TRANSFERRING ECONOMIC EVALUATIONS TO MIDDLE INCOME COUNTRIES. International Journal of Technology Assessment in Health Care 31:6, pages 442-448.
Crossref
Crossref
C. Daniel Mullins, Nneka C. Onwudiwe, Gabriela Tannus Branco de Araújo, Wen Chen, Jianwei Xuan, Aleš Tichopád & Shanlian Hu. (2014) Guidance Document: Global Pharmacoeconomic Model Adaption Strategies. Value in Health Regional Issues 5, pages 7-13.
Crossref
Crossref
V. Borges de Santana, L. Bertocco de Paiva Haddad, T. Morgado Conte, A. Cortez Rizzon, V. Miranda Barbosa, W. ShieldIIIIII, W. Andraus & L. Augusto Carneiro D’Albuquerque. (2014) MELD Score and Albumin Replacement Are Related to Higher Costs During Management of Patients With Refractory Ascites. Transplantation Proceedings 46:6, pages 1760-1763.
Crossref
Crossref
A.L. Soilly, C. Lejeune, C. Quantin, S. Bejean & J.B. Gouyon. (2014) Economic analysis of the costs associated with prematurity from a literature review. Public Health 128:1, pages 43-62.
Crossref
Crossref
J. Hendriks, F. Tomini, T. van Asselt, H. Crijns & H. Vrijhoef. (2013) Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace 15:8, pages 1128-1135.
Crossref
Crossref
Eduardo A. Undurraga, Yara A. Halasa & Donald S. Shepard. (2013) Use of Expansion Factors to Estimate the Burden of Dengue in Southeast Asia: A Systematic Analysis. PLoS Neglected Tropical Diseases 7:2, pages e2056.
Crossref
Crossref
Marc Suhrcke, Till A Boluarte & Louis Niessen. (2012) A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries. BMC Public Health 12:1.
Crossref
Crossref
Saskia Knies, Math J.J.M. Candel, Annelies Boonen, Silvia M.A.A. Evers, Andre J.H.A. Ament & Johan L. Severens. (2012) Lost Productivity in Four European Countries among Patients with Rheumatic Disorders. PharmacoEconomics 30:9, pages 795-807.
Crossref
Crossref
E. Sicuri, C. Davy, M. Marinelli, O. Oa, M. Ome, P. Siba, L. Conteh & I. Mueller. (2011) The economic cost to households of childhood malaria in Papua New Guinea: a focus on intra-country variation. Health Policy and Planning 27:4, pages 339-347.
Crossref
Crossref
Antonio Roman, Joan A. Barberà, Pilar Escribano, Maria L. Sala, Laia Febrer, Itziar Oyagüez, Eliazar Sabater & Miguel Á. Casado. (2012) Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension. Applied Health Economics and Health Policy 10:3, pages 175-188.
Crossref
Crossref
Andres Pichon-Riviere, Federico Augustovski, Sebastián García Martí, Sean D. Sullivan & Michael Drummond. (2012) TRANSFERABILITY OF HEALTH TECHNOLOGY ASSESSMENT REPORTS IN LATIN AMERICA: AN EXPLORATORY SURVEY OF RESEARCHERS AND DECISION MAKERS. International Journal of Technology Assessment in Health Care 28:2, pages 180-186.
Crossref
Crossref
Aukje van Gestel, Carroll A. Webers, Johan L. Severens, Henny J. Beckers, Nomdo M. Jansonius, Fred Hendrikse & Jan S. Schouten. (2012) The long‐term outcomes of four alternative treatment strategies for primary open‐angle glaucoma. Acta Ophthalmologica 90:1, pages 20-31.
Crossref
Crossref
Subarna Thirugnanam, Ruxandra Pinto, Deborah J Cook, William H Geerts & Robert A Fowler. (2012) Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. Critical Care 16:2, pages R43.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
293
304
.
Silke B. Wolfenstetter. (2011) Conceptual Framework for Standard Economic Evaluation of Physical Activity Programs in Primary Prevention. Prevention Science 12:4, pages 435-451.
Crossref
Crossref
Chung-Wei Christine Lin, Marion Haas, Chris G. Maher, Luciana A. C. Machado & Maurits W. van Tulder. (2011) Cost-effectiveness of guideline-endorsed treatments for low back pain: a systematic review. European Spine Journal 20:7, pages 1024-1038.
Crossref
Crossref
D Lier, S Ross, S Tang, M Robert & P Jacobs. (2011) Trans-obturator tape compared with tension-free vaginal tape in the surgical treatment of stress urinary incontinence: a cost utility analysis. BJOG: An International Journal of Obstetrics & Gynaecology 118:5, pages 550-556.
Crossref
Crossref
Jose L. López-Sendón, David Martí-Sánchez, Belén Martí, Itziar Oyagüez & Miguel Ángel Casado. (2013) Análisis coste-efectividad de eplerenona en pacientes con insuficiencia cardiaca post-infarto agudo de miocardio. PharmacoEconomics Spanish Research Articles 8:2, pages 39-50.
Crossref
Crossref
Yara A. Halasa, Betzana Zambrano, Donald S. Shepard, Gustavo H. Dayan & Laurent Coudeville. (2011) Economic Impact of Dengue Illness in the Americas. The American Journal of Tropical Medicine and Hygiene 84:2, pages 200-207.
Crossref
Crossref
Ulla Walter, Marc Suhrcke, Miriam G Gerlich & Till A Boluarte. (2010) The opportunities for and obstacles against prevention: the example of Germany in the areas of tobacco and alcohol. BMC Public Health 10:1.
Crossref
Crossref
Santiago Moreno, Juan González, Ingrid Lekander, Belén Martí, Itziar Oyagüez, Rainel Sánchez-de la Rosa & Miguel Angel Casado. (2010) Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clinical Therapeutics 32:13, pages 2232-2245.
Crossref
Crossref
Christoph T. H. Baltin, Christina Smaczny & Thomas O. Wagner. (2011) Medikamentöse Behandlung von Mukoviszidose – Kostenstruktur und Einsparpotenzial der ambulanten BehandlungDrug Treatment of Cystic Fibrosis – Cost Patterns and Savings Potential for Outpatient Treatment. Medizinische Klinik 105:12, pages 887-900.
Crossref
Crossref
Patricia R. Blank, Konstantin J. Dedes & Thomas D. Szucs. (2010) Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer. PharmacoEconomics 28:8, pages 629-647.
Crossref
Crossref
Brigitte A.B. Essers, Shanley C. Seferina, Vivianne C.G. Tjan-Heijnen, Johan L. Severens, Annoesjka Novák, Marjolein Pompen, Ulrich H. Oron & Manuela A. Joore. (2010) Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands. Value in Health 13:4, pages 375-380.
Crossref
Crossref
Damian G. Walker, Yot Teerawattananon, Rob Anderson & Gerry Richardson. 2010. Evidence-Based Decisions and Economics. Evidence-Based Decisions and Economics
56
66
.
Ian Shemilt, Miranda Mugford, Luke Vale, Kevin Marsh, Cam Donaldson & Michael Drummond. (2010) Evidence synthesis, economics and public policy. Research Synthesis Methods 1:2, pages 126-135.
Crossref
Crossref
Oliver Rivero-Arias & Alastair Gray. (2010) The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials. Value in Health 13:1, pages 34-41.
Crossref
Crossref
A. Sanz-Granda. (2009) Análisis probabilístico de minimización de costes de darbepoetin alfa frente a epoetina alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica. Valoración en la práctica clínica española. Farmacia Hospitalaria 33:4, pages 208-216.
Crossref
Crossref
Jean-Eric Tarride, Gord Blackhouse, Matthias Bischof, Elizabeth C. McCarron, Morgan Lim, Ilia L. Ferrusi, Feng Xie & Ron Goeree. (2009) Approaches for Economic Evaluations of Health Care Technologies. Journal of the American College of Radiology 6:5, pages 307-316.
Crossref
Crossref
Christian S. van der HilstAlexander J. C. IJtsma, Maarten J. H. Slooff & Elisabeth M. TenVergert. (2008) Cost of Liver Transplantation. Medical Care Research and Review 66:1, pages 3-22.
Crossref
Crossref
A. Sanz-Granda. (2009) Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice. Farmacia Hospitalaria (English Edition) 33:4, pages 208-216.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
Crossref